Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript

Impact · against what's priced in

The expanded collaboration between Regeneron and Sanofi is moderately positive but doesn't shift the core investment thesis, as it primarily serves as a long-term hedge against patent cliffs. For REGN, this supports the need to replace Eylea revenue but does not address the immediate clinical failures or obesity pipeline milestones that currently drive the stock's valuation.

REGN+0.15

Challenges what's priced in